The aims of this study were to 1) quantify changes in angiogenesis during follicular growth in a primate model; 2) investigate the molecular regulation using in situ hybridization of vascular endothelial growth factor (VEGF), its receptor, Flt-1, the angiopoietins (Ang-1 and Ang-2), and their receptor, Tie-2; 3) elucidate the role of VEGF in follicular angiogenesis by blocking its action by treatment with a soluble truncated form of the Flt-1 receptor, (VEGF Trap A40 ). Changes in angiogenesis were quantified using bromodeoxyuridine to obtain a proliferation index, and CD31 immunocytochemistry to visualize endothelial cell area. Percentage of proliferating endothelial cells was calculated by double labeling for bromodeoxyuridine and CD31. Vascularization was first observed in follicles containing four granulosa cell layers. A significant increase in proliferation in the thecal layer was observed from the early to late secondary stage, and dual staining showed that 25% of proliferating cells were of endothelial cell origin. VEGF messenger RNA (mRNA) was expressed in granulosa cells with an increase of grain density from late secondary to tertiary follicles. Ang-1 was weakly expressed in the theca of tertiary follicles. Ang-2 mRNA was not detected in any follicles. The mRNA for the Flt-1 and Tie-2 receptors was localized in endothelial cells of the theca. Unexpectedly, Tie-2 mRNA was also found in granulosa cells of early follicular stages and its translation was confirmed by immunocytochemistry. VEGF trap treatment for 3 days resulted in an 87% decrease of proliferation in the theca of secondary and tertiary follicles, a reduction in endothelial cell area and a marked decline in Flt-1 mRNA expression. Granulosa cell proliferation also decreased. These results show that onset and establishment of the follicle vasculature takes place early during follicular development. The ability of VEGF trap treatment to severely restrict follicular angiogenesis establishes that VEGF is the major regulator of this process in the primate ovary. (Endocrinology 142: 3244 -3254, 2001) 
thelial cell origin. VEGF messenger RNA (mRNA) was expressed in granulosa cells with an increase of grain density from late secondary to tertiary follicles. Ang-1 was weakly expressed in the theca of tertiary follicles. Ang-2 mRNA was not detected in any follicles. The mRNA for the Flt-1 and Tie-2 receptors was localized in endothelial cells of the theca. Unexpectedly, Tie-2 mRNA was also found in granulosa cells of early follicular stages and its translation was confirmed by immunocytochemistry. VEGF trap treatment for 3 days resulted in an 87% decrease of proliferation in the theca of secondary and tertiary follicles, a reduction in endothelial cell area and a marked decline in Flt-1 mRNA expression. Granulosa cell proliferation also decreased. These results show that onset and establishment of the follicle vasculature takes place early during follicular development. The ability of VEGF trap treatment to severely restrict follicular angiogenesis establishes that VEGF is the major regulator of this process in the primate ovary. (Endocrinology 142: 3244 -3254, 2001) A NGIOGENESIS is initiated early during follicular development and continues throughout follicular growth (1) . Although small preantral follicles have no vascular supply of their own, antral follicles acquire a vascular sheath in the theca; the capillaries do not penetrate the membrana propria but they expand during the growth of the follicle (2) . Differences in vascular development appear to be crucial in selection of the ovulatory follicle. Increased vascularization of individual follicles results in preferential delivery of gonadotropins and suggests that blood flow to individual follicles plays an instrumental role in the selective maturation of preovulatory follicles (3) . Little is known about the molecular regulation of the vascular development during follicular growth and atresia and about the physiological role of the various factors involved. The aim of this study was to address this issue, first by quantifying changes in angiogenesis during follicular growth in the marmoset monkey using quantitative immunocytochemistry for bromodeoxyuridine (BrdU) as a proliferation marker and CD31 as a specific endothelial cell marker. Second, the molecular regulation of angiogenesis was studied using quantitative in situ hybridization for angiogenic factors and their receptors; vascular endothelial growth factor (VEGF); its receptor, Flt-1; the angiopoietins (Ang-1 and Ang-2); and their receptor, Tie-2. VEGF is a principal angiogenic factor and its presence in the ovarian follicle has been described (4 -9) ; the angiopoietins act in concert with VEGF to regulate angiogenesis and induce stability in newly formed blood vessels (10, 11) . No information is available as to their presence in the primate follicle.
Because one of the most likely factors involved in the regulation of follicular angiogenesis is VEGF, we investigated its physiological role by inhibiting its action in vivo by treating marmosets with a soluble truncated form of the Flt receptor, Flt-1-Fc (VEGF Trap A40 ). VEGF Trap A40 has a high affinity for all forms of endogenous VEGF, preventing VEGF from binding to its receptors. We examined the effects of VEGF inhibition on thecal vascularization and on the expression of angiogenic factors and their receptors in growing and atretic follicles.
Materials and Methods
In the current study, ovaries obtained during our previous investigation (12) were used, in which marmosets were treated with VEGF Trap A40 from the time of ovulation (luteal day 0) until luteal day 3 and effects on luteal angiogenesis compared with that of controls. Because the successful suppression of luteal angiogenesis was demonstrated (12) , it was rational to use the same approach for studying effects on follicular vascularization.
Flt-1-Fc (VEGF Trap A40 )
As described previously (12) the VEGF Trap A40 used in these experiments comprised a portion of the extracellular domain of VEGF receptor Flt-1 fused to the Fc portion of human IgG. This soluble truncated form of the Flt-1 receptor has been demonstrated to neutralize circulating VEGF and inhibit its action (12) . Levels of circulating bound and unbound VEGF Trap A40 in plasma of marmosets were measured and by calculation of the ratio of bound to unbound VEGF trap it was shown that 99% of the circulating VEGF trap was unmodified and remained available for neutralization of endogenous VEGF (12) .
Animals
Adult female common marmoset monkeys (Callithrix jacchus) with a body weight of approximately 350 g and regular ovulatory cycles were housed together with a younger sister or prepubertal female as described previously (13) . Blood samples were collected three times per week by femoral venipuncture without anesthesia and plasma was subjected to progesterone assay to confirm normal ovulatory cycles.
Treatment
Experiments were carried out in accordance with the Animals (Scientific Procedures) Act, 1986 and approved by the local Ethical Review Process Committee. To synchronize timing of ovulation, animals were treated with 1 g PGF 2␣ analog (Planate, Coopers Animals Health Ltd., Crewe, UK) im during the mid to late luteal phase to induce luteolysis. This treatment is normally followed by ovulation 10 days later (14) . Four marmosets were treated with VEGF trap at a dose of 25 mg/kg, approximately 1 ml injected at two sc sites over the abdominal region. The same number of controls were similarly treated with vehicle alone. Treatment commenced on the day of presumed ovulation (luteal day 0) and was repeated on days 1 and 2. On day 3 the animals were injected iv with 20 mg BrdU (Roche Molecular Biochemicals, Essex, UK) in saline. One hour later, the animals were sedated using 100 l ketamine hydrochloride (Parke-Davis Veterinary, Pontypool, Gwent, UK) and killed with an iv injection of 400 l Euthetal (sodium pentobarbitone; Rhone Merieux, Harlow, Essex, UK). After cardiac exsanguination via a heparinized syringe, ovaries were removed immediately and fixed in 4% paraformaldehyde. After 24 h, the ovaries were dehydrated and embedded in paraffin according to standard procedures.
Immunocytochemistry
Establishment of the thecal vascular network was studied by 1) quantifying the number of mitotic cells stained for BrdU, 2) identifying endothelial cells using CD31 staining, and 3) determining the incidence of colocalization of BrdU and CD31.
Tissue sections (5 m) were cut onto 3-aminopropyltriethoxy saline Tespa-coated slides (Sigma, St Louis, MO) for immunocytochemistry. Sections were dewaxed in xylene, rehydrated in descending concentrations of ethanol, and washed in distilled water. For BrdU and CD31 immunostaining, antigen retrieval was performed by pressure cooking (Tefal Clypso pressure cooker; Tefal, Essex, UK) sections in 0.01 m citrate buffer, pH 6, for 6 min at high pressure setting 2. Slides were then left for 20 min in hot buffer and washed in Tris-buffered saline (TBS) (0.05 mol/liter Tris, 9 g/liter NaCl). To reduce nonspecific binding sections were blocked in normal rabbit serum (NRS, 1:5 diluted in TBS) for 30 min. Primary antibodies CD31 (mouse antihuman CD31; DAKO Corp., Ely, Cambridgeshire, UK) or BrdU (mouse anti-BrdU; Roche Molecular Biochemicals) were diluted 1:20 or 1:30 in TBS, respectively. Incubation was carried out overnight at 4 C. Slides were washed three times in TBS. Incubation with the secondary antibody (rabbit antimouse Ig, 1:60 diluted in TBS (DAKO Corp.) was performed for 40 min at room temperature followed after 2 washes in TBS by incubation of the APAAP complex (1:100 dilution in TBS, DAKO Corp.) for 40 min at room temperature. Visualization was performed using 500 l/slide 4-nitro blue tetrazolium chloride solution containing 45 l NBT substrate (Roche Molecular Biochemicals), 10 ml NBT buffer, 35 l Xphosphate, and 10 l levamisole. Sections for BrdU were counterstained with hematoxylin, whereas sections for CD31 were not counterstained so that quantitative image analysis could be performed. For dual labeling, slides were incubated first with CD31 and visualization with fast red (Sigma, St. Louis, MO). The fast red solution contained 1 mg fast red in 1 ml fast red buffer (20 mg naphtol AS-MX phosphate, 2 ml dimethyl formamide, 98 ml 0.1 m Tris, pH 8.2). Staining for CD31 was followed by BrdU, which was visualized with NBT as described above.
Tie-2 immunocytochemistry
Tissue sections were dewaxed, rehydrated, and placed into TBS as described above. To reduce nonspecific staining, sections were incubated for 20 min in NRS containing avidin, washed in TBS, and incubated for another 20 min in NRS biotin (Avidin/Biotin blocking Kit; Vector Laboratories, Inc., Burlingame, CA). After two washes in TBS, slides were exposed overnight at 4 C to the Tie-2 antibody (mouse-antirat Tie-2 monoclonal, 1:500 dilution; Regeneron Pharmaceuticals, Inc., Tarrytown, NY). Slides were washed two times in TBS followed by incubation for 30 min at room temperature with the secondary antibody (rabbit-antimouse-biotinylated antibody, 1:200 dilution; DAKO Corp.). For signal amplification the ABC (avidin-biotin-complex) method was used. After incubation with ABC-HPR (horse raddish peroxidase) (DAKO Corp.) for 30 min at room temperature and two washes in TBS-Tween, signal enhancement was achieved by exposing the slides to biotinylated tyramide (GenPoint kit; DAKO Corp.) for 20 min at room temperature, followed by incubation with ABC-AP (alkaline phosphatase) for 30 min. The signal was detected using NBT substrate as described above.
In situ hybridization
In situ hybridization was performed as described previously (15) using complementary RNA probes for human VEGF, Flt, Ang-1, Ang-2, and Tie-2. Sense and antisense probes were prepared using an RNA transcription kit (Ambion, Inc., Austin, TX) and labeled with 35 S uridine 5Ј-triphosphate (NEN Life Science Products, Boston, MA). Deparaffinized sections were treated with 0.1 n HCl and then digested in proteinase K (5 g/ml, Sigma) for 30 min at 37 C. After prehybridization for 2 h at 50 C for VEGF and 55 C for Flt, Ang-1, Ang-2, and Tie-2 subsequent hybridization was performed in a moist chamber overnight at 50 or 55 C. High stringency post hybridization washings and RNase treatment were used to remove excess probe. Slides were then dehydrated, dried, and dipped in Ilford G5 liquid emulsion (H. A. West, Edinburgh, UK). Exposure times for VEGF, Flt, Ang-2, and Tie-2 were 2, 4, 7, and 7 weeks, respectively. Slides were subsequently developed (D19 developer; Kodak, Rochester, NY) and fixed (Kodak GBX Fixer/ Replenisher). All slides were counterstained with hematoxylin (RichardAllan, Richland, MI), dehydrated, and mounted.
Analysis of data
Morphological characterization of ovarian follicles. Stages of follicular development were defined as follows: primordial (oocytes surrounded by single flat layer of follicle epithelial cells), primary (single layer of cuboidal granulosa cells), early secondary (two to four layers of granulosa cells), late secondary (more than four granulosa cell layers, no antrum), and tertiary follicles (follicles containing an antrum). Follicles were classified as healthy if they contained a normal shaped oocyte surrounded by granulosa cells that were regularly apposed on an intact basement membrane with normal appearance of granulosa cell nuclei without signs of pycnosis. Follicles not fulfilling these criteria were classified as atretic.
Only follicles with a visible oocyte were considered to ensure proper follicular counting and classification. In each ovary a total of 20 -30 primordial, 8 -10 primary, 5-10 early secondary, 5-8 late secondary, and 4 -6 tertiary healthy and atretic follicles were analyzed, respectively.
Quantification of immunocytochemistry and in situ hybridization. Quantitative analysis for BrdU and CD31 immunocytochemistry and in situ hybridization was performed using an image analysis system linked to an Olympus Corp. camera, and the data were processed using ImagePro plus Version 3.0 for Windows (Microsoft Corp., Reading, Berkshire, UK). In all follicles, the whole cross sections were analyzed. Captured images were thresholded, and the theca and granulosa cell compartment was outlined and analyzed separately. CD31 labeling. The endothelial cell area (i.e. CD31-positive cells) was measured at ϫ200 magnification. The captured gray scale image was thresholded and converted to a binary image. The whole area of the theca compartment and the CD31-positive area within the compartment was measured. The CD31-positive area was then calculated per unit area of the theca compartment and expressed as a mean value for the number of follicles assessed within each follicular stage and per animal.
Colocalization of CD31 and BrdU. The number of dual-stained cells (BrdUand CD31-positive cells) and the total number of proliferating cells (i.e. BrdU-positive cells) were counted in the theca compartment. The proportion of proliferating endothelial cells (dual-stained cells) was expressed as a percentage of the total number of proliferating cells. The mean value was calculated for the number of follicles assessed within each follicular stages and per animal.
In situ hybridization. Slides were analyzed qualitatively under lightfield and quantitatively under darkfield conditions at ϫ 400 magnification. As a value for gene expression the grain density (number of grains/m 2 ) was measured. The image analyses system was set up to identify mRNA expressing cells, to outline them and measure the grain density within these cells. Tissue background density was measured for each antisense slide and subtracted from the measurements. The mean value was calculated for the number of follicles assessed within each follicular stage and per animal.
Statistical analysis. Data obtained for normal follicular angiogenesis were tested for significant differences using ANOVA followed by Duncans multiple range test. Effects of the treatment as compared with controls, were determined using a two-tailed, unpaired t test. Differences were considered to be significant if P less than 0.05. The tests were performed using SPSS version 6.1 for Macintosh (SPSS, Inc., Chicago, IL). All values are given as mean Ϯ sem.
Results

Vascular development during normal follicular growth
CD31 immunostaining. Endothelial cell staining was absent in earliest follicular stages (Fig. 1A) and first visible in follicles containing more than four granulosa cell layers, i.e. the late secondary stage (Fig. 1B) . The endothelial cell area was somewhat increased in tertiary follicles (Fig. 1C) compared with late secondary follicles; however, this was not significant. In contrast, the endothelial cell area was markedly reduced (P Ͻ 0.05) by 63-71% in atretic follicles (Fig. 1D ) compared with secondary and tertiary follicles (Fig. 2A) .
BrdU immunostaining. Cell proliferation at different stages of follicular development is illustrated in Fig. 3 and quantified in Fig. 2 . In early secondary follicles a theca like formation is visible in which single cells proliferate (Fig. 3A) . In the late (Fig. 3B) secondary stage a significant 15-fold increase of theca proliferation was found compared with the early secondary follicles (Fig. 2B) . No further increase was observed in tertiary follicles (Figs. 3C and 2B ). Proliferation in the theca was markedly reduced (P Ͻ 0.05) by 76% during follicular atresia (Figs. 3D and 2B) .
In primary follicles, BrdU staining indicative of cell proliferation was found in the granulosa. The proliferation index of the granulosa (Fig. 2C) increased significantly from the primary to early and to late secondary follicles. The proliferation index of late secondary follicles was not different compared with the tertiary stage. In atretic follicles, proliferation of the granulosa was severely reduced (P Ͻ 0.05).
Colocalization of CD31 and BrdU
BrdU-positive cells of the theca in early secondary follicles were not dual stained with CD31, indicating that cells other than endothelial cells proliferate in early secondary stages. The earliest clear evidence of vascular proliferation was found in the theca of late secondary follicles. In these follicles, 25 Ϯ 5% of proliferating cells were dual stained. The percentage of double-labeled proliferating cells in tertiary follicles was 30 Ϯ 5% (Fig. 3C, inset) .
In situ hybridization
VEGF mRNA was first detected in late secondary follicles (Fig. 4A) , grain density in the granulosa and theca being similar (0.005 Ϯ 0.001 grains/m 2 ). A significant increase in VEGF mRNA expression was observed within the granulosa of follicles in the tertiary stage (Fig. 5A) , whereas in these follicles VEGF expression in the theca was significantly lower (0.003 Ϯ 0.001 grains/m 2 ). During atresia, the VEGF expression was significantly reduced by 55% in the granulosa and was no longer detectable in the theca. The Flt receptor mRNA was expressed in endothelial cells of the theca of late secondary follicles (Fig. 4B ) and increased significantly in the theca of tertiary follicles (Fig. 5B) . During follicular atresia, a significant 50 -70% decrease was observed compared with late secondary and tertiary follicles. Ang-1 mRNA appeared to be expressed at a very low level (0.003 Ϯ 0.0005 grains/ m 2 ) in the theca of tertiary follicles. No differences in grain density were found between tertiary and atretic follicles. No Ang-2 expression was found in follicles at any stages investigated. Ang-2 mRNA was moderately expressed only by a subset of blood vessels within the ovarian stroma. Ang-1 and Ang-2 mRNA were highly expressed in sections of marmoset placenta included in the run as a positive control (not shown). Tie-2 mRNA expression was found in tertiary follicles (Fig. 4C ) mainly confined to the endothelium of the theca cell compartment. During follicular atresia, expression of Tie-2 appeared to cease and image analysis revealed a significant 70% decrease of grain density in the theca compared with healthy tertiary follicles (Fig. 5C ). Unexpectedly, Tie-2 mRNA expression was found in earliest follicular stages (Fig. 6A) being localized in the epithelial cells of primordial follicles. The expression of the Tie-2 receptor was maintained in the granulosa cells of primary and early secondary follicles (Fig. 6B) . The expression of Tie-2 in the granulosa began to decrease significantly in late secondary follicles (Fig. 6D ) and was barely detectable in the granulosa of tertiary follicles (Fig. 6, C and D) . In a few follicles, Tie-2 expression was maintained in cumulus cells (Fig. 6C) .
Tie-2 immunocytochemistry
Because Tie-2 expression is ordinarily specific to vascular endothelial and certain hematopoietic cells, the mRNA expression in granulosa cells was an unexpected finding. To confirm that Tie-2 mRNA is translated into protein, immunocytochemistry for Tie-2 was carried out. As for Tie-2 mRNA, the Tie-2 receptor protein was localized in the epithelial cells of primordial follicles (Fig. 6E, inset) , in the granulosa cells of primary, early, and late secondary follicles (Fig.  6E) as well as in the endothelium of the theca of tertiary follicles (Fig. 6F) . 
Vascular development during folliculogenesis after VEGF trap treatment
The treatment with VEGF trap effected the endothelial cell area, cell proliferation, and the expression of angiogenic factors in the theca of follicles. Furthermore, proliferation in the granulosa was affected by the treatment.
In the theca of tertiary follicles, a significant 42% reduction of the endothelial cell area was observed (Figs. 7 and 8A ) after treatment. Proliferation decreased significantly by 87% after VEGF trap treatment in late secondary and tertiary follicles (Figs. 7 and 8B ). Dual staining showed that in controls, 25-30% of proliferating cells are of endothelial cell origin. The 87% decrease indicates that in addition to endothelial cell proliferation, proliferation of other cells are compromised by the treatment. The lack of double-labeled cells with BrdU and CD31 revealed that treatment inhibited endothelial cell proliferation (Fig. 7D) .
The VEGF trap treatment did not affect proliferation of the granulosa cells in primary, early secondary, and atretic follicles (Fig. 8C) . After treatment, a significant decrease of 42% proliferation in the granulosa was observed in late secondary (Fig. 8C) follicles. In tertiary follicles there was also an apparent decrease after VEGF trap treatment but, because of a high sem, this was not significant.
The Flt receptor expression was severely inhibited by the VEGF trap treatment (Fig. 9) ; it was significantly reduced by 70% in late secondary, 87% in tertiary, and 73% in atretic follicles indicating a switch off of the Flt gene (Fig. 10) .
VEGF expression appeared to be increased in late secondary and tertiary follicles after treatment. However, due to a high sem this apparent increase was not statistically signif- Note the increase in expression in the granulosa and the decrease in the theca compartment in tertiary follicles compared with late secondary follicles. In the lower right corner a small piece of the corpus luteum is seen, in which high mRNA expression is visible. B, Flt expression increased in the theca from late secondary to tertiary follicles. The message was barely detectable in atretic follicles (A). C, The angiopoietin receptor Tie-2 is localized in the endothelium (arrowheads) of the theca [broken gray line indicates the border of granulosa (Gr) and theca (Th)] of tertiary follicles. Bar, 100 m.
FIG. 5. Quantitative analyses of mRNA expression of VEGF (A), Flt (B)
, and Tie-2 (C). Different letters indicate significant differences between different follicle classes. Pr, Primordial; P, primary; ES, early secondary; LS, late secondary; T, tertiary; A, atretic.
FIG. 6. Tie-2 mRNA and protein expression in the granulosa of different follicle types. A, Tie-2 mRNA expression is found in epithelial cells in primordial follicles (Pr) and in the granulosa of primary follicles (P). Bar, 50 m. The inset shows a sense slide with the absence of grains in these follicles. B, In secondary (S) follicles Tie-2 mRNA is expressed in all granulosa cell layers (Gr). The left panel shows the lightfield picture, the right the darkfield image. C, Tie-2 expression in a tertiary (T) follicles under lightfield (left) and darkfield (right) conditions. Tie-2 expression has declined markedly except in the granulosa cell layer next to the oocyte (arrows), whereas Tie-2 mRNA is beginning to be expressed in endothelial cells of the theca (arrowheads). Bar, 100 m. D, Quantitative analyses of Tie-2 grain density in the granulosa of different follicles icant. No difference of expression in the theca was found for Ang-1 and its receptor Tie-2 after VEGF trap. Tie-2 expression in the granulosa of early follicular stages was also unaffected by the treatment.
Discussion
This study shows that the onset of follicular vascularization begins at the early secondary stage, increases during follicular growth, and declines during follicular atresia in the marmoset. Examination of the molecular regulation of this process by in situ hybridization suggested an important role for VEGF, which was highly expressed in the granulosa cells of secondary and tertiary follicles, whereas its receptor Flt was expressed in endothelial cells of the theca layer. An essential role for VEGF in the process of follicular vascularization was established by treatment of marmosets with VEGF trap to neutralize the action of VEGF, which resulted in suppression of angiogenesis in the follicles.
The fact that proliferation was first seen in the theca in early secondary follicles in which endothelial cell staining was absent shows that the establishment of the theca compartment precedes angiogenesis. As the follicle develops, and more than four granulosa cell layers become established, staining of endothelial cells was detectable demonstrating the onset of theca vascularization. Proliferation in the thecal layer was markedly increased. Double labeling revealed that 25% of all proliferating cells are of endothelial cell origin. In tertiary follicles, theca proliferation continues characterized by further intense endothelial cell proliferation.
With regard to the molecular processes regulating these events, the observation that the expression of VEGF was highest in the granulosa, whereas its receptor Flt was extypes. Pr, Primordial; P, primary; ES, early secondary; LS, late secondary; T, tertiary; A, atretic. Different letters indicate significant differences. Note the marked decrease of grain density between early and late secondary follicles. E and F, Immunocytochemistry staining for Tie-2 is shown. pressed in theca endothelial cells of tertiary follicles suggests VEGF acts mainly in a paracrine manner to stimulate vascularization in the theca. The increase in both VEGF and Flt message in tertiary follicles could be explained by the fact that at that stage follicles undergo rapid growth and antrum formation. To keep pace with this growth, the vasculature has to expand intensively; therefore, VEGF up-regulation is required to induce this vascular development.
Tie-2 expression was localized in the theca endothelial cells of tertiary follicles. It has been shown that Tie-2 activated by its ligand Ang-1 promotes endothelial survival and stabilization of newly formed vessels (10, 16, 17) . Thus, it is suggested that Tie-2 could be required to maintain the integrity of theca vessels. It was surprising to discover that the Tie-2 receptor (mRNA and protein), which is believed to be an endothelial-specific tyrosine kinase receptor, was located in the granulosa cells of primordial, primary, and early secondary follicles. The highest levels of Tie-2 mRNA were detected in granulosa cells of early follicular stages. A decrease was observed in late secondary follicles whereas in tertiary follicles the message disappeared in the granulosa except in the granulosa cells of the cumulus cells proximal to the oocyte. Most growth hormones use receptors of the tyrosine kinase family (18 -21) . Potentially, this receptor may be used by other ligands than angiopoietins and may be involved in early follicular maturation. However, at this time the function of Tie-2 expression in early follicular stages is unknown.
The relationship between onset of atresia and changes in the vasculature is controversial because of difficulties in establishing the temporal relationship between the two processes. While in the human, a dense capillary network has been reported to remain in atretic follicles (1), decreased vascularity has been observed in atretic follicles of various other mammals (3, 22, 23) . In this study, VEGF expression in the granulosa and Flt-1 and Tie-2 mRNA expression in the theca was significantly reduced in atretic follicles. Consistent with this observation, endothelial cell proliferation and the endothelial cell area were significantly reduced in atretic follicle in the marmoset. Thus, the mRNA for a principal angiogenic inducer and its receptor are down-regulated during follicular atresia, which may lead to a decrease in endothelial cell proliferation and survival.
Administration of VEGF antibodies or receptor-based VEGF trap treatment has proven to be a powerful tool by which the actions of VEGF on luteal angiogenesis and function can be investigated (12, 24, 25) . This is the first study examining effects of VEGF inhibition by VEGF trap on follicular angiogenesis. After VEGF trap treatment, a reduction of proliferating cells in the theca was found in late secondary and tertiary follicles. The endothelial cell area was also decreased in tertiary follicles. The increased VEGF mRNA in normal tertiary follicles may indicate an increased requirement for VEGF at this stage in development and this, in turn may render them more vulnerable to VEGF inhibition by VEGF trap.
After treatment with VEGF trap, the proliferation in the theca was reduced by up to 87%. Dual staining in controls revealed that only 25-30% of the proliferating cells are of endothelial cell origin. Thus, reduction of cellular prolifer- ation in the theca indicates that the treatment had a secondary inhibitory effect on proliferation of nonendothelial cells in the theca. Furthermore, proliferation of the granulosa of late secondary follicles was reduced after treatment. The likeliest explanation for these findings is that attenuation of the follicular vasculature affected the availability of growth factors, hormones or oxygen to the growing follicle. In addition, as VEGF promotes vascular permeability (26, 27) as well as angiogenesis, permeability may have been altered such that larger molecules like LH cannot penetrate the endothelium and reach the theca cells. In response to reduced exposure to LH their proliferation rate would be reduced. The collateral finding of decreased proliferation of thecal and granulosa cells suggests that this impairment of the development of the thecal vasculature exerts a secondary deleterious effect on follicular development. This hypothesis will be addressed in future studies designed to determine whether prolonged application of VEGF trap early in the cycle impedes the maturation of tertiary follicle and ovulation.
Finally, VEGF trap treatment had severe effects on the Flt receptor mRNA expression. The marked decrease in grain density after the treatment indicates that the Flt gene was switched off due to the lack of functional VEGF, implying that VEGF regulates its own receptor expression in follicles as observed in other tissues (28 -30) .
In conclusion, this study provides the first clear experimental support that VEGF, acting in a paracrine manner, is the major inducer of vascular development during follicular growth and that the ability to manipulate its activity using an antagonist such as VEGF Trap A40 could have important clinical applications. It is tempting to speculate that at least two ovarian disorders, i.e. the polycystic ovarian syndrome and the ovarian hyperstimulation syndrome associated with pathological angiogenesis, hypervascularity, and hyperpermeability, may be responsive to an anti-VEGF treatment and VEGF trap may be a possible competent therapeutic candidate. and VEGF trap-treated animals (white bars) of different follicle classes. Pr, Primordial; P, primary; ES, early secondary; LS, late secondary; T, tertiary; A, atretic. Different letters indicate significant differences. Note that after VEGF trap treatment Flt expression was decreased significantly in all follicle classes.
